Overview

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Status:
Recruiting
Trial end date:
2021-11-14
Target enrollment:
Participant gender:
Summary
This is a drug-drug interaction study to assess the effects of PF-07321332/ritonavir and ritonavir on the Pharmacokinetic (PK) of dabigatran in healthy volunteers. PK will be evaluated for PF-07321332 and ritonavir. Dabigatran is being utilized as a P-gp substrate
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Dabigatran
Ritonavir